U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104110) titled 'Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer' on July 29.
Brief Summary: This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Prostatic Neoplasms
Intervention:
DRUG: QLH12016
oral AR PROTAC
DRUG: abiraterone acetate
oral CYP17 inhibitor
DRUG: enzalutamide
oral androgen receptor inhibitor
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qilu P...